Drug
Msb0010445
Msb0010445: highest development phase Phase 2, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| MSB0010445 (0.3 milligram per kilogram [mg/kg]) NCT01973608 | Phase 2 | Melanoma |
Latest
No recent events.
Follow Msb0010445 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.